Boston Life Sciences, Inc. To Present At Friedland Investment Events East Coast Biotech, Medical And Healthcare Luncheons

Main Category: Neurology / Neuroscience
Also Included In: Parkinson's Disease;  ADHD;  Clinical Trials / Drug Trials
Article Date: 13 Jul 2006 - 0:00 PDT

email to a friend   printer friendly   opinions  

Boston Life Sciences, Inc. (Nasdaq: BLSI), a biotechnology company focused on diagnostic and therapeutic products for diseases of the Central Nervous System (CNS), today announced that it will be presenting at Friedland Investment Events East Coast Biotech, Medical and Healthcare Luncheons on July 18th, 19th and 20th in Philadelphia, New York and Boston. Dr. Mark Pykett, President & Chief Operating Officer, or Mr. Ken Rice, Executive Vice President and Chief Financial Officer, will be presenting a Company update which will include a review of the company's products, management and recent company developments.

Registration is required to attend these luncheons. Complimentary tickets are available to members of the financial community and select investors by applying online at http://www.friedlandworldwide.com.

About Friedland Investment Events

Friedland Investment Events LLC is the world's largest sponsor of financial and investment events, sponsoring hundreds of events annually, in 18 US cities and 3 European cities. These events include all-day conferences, breakfasts, luncheons and cocktail receptions. Friedland Investment Events LLC is an affiliate of Friedland Capital Inc. and Friedland Corporate Investor Services LLC (http://www.friedlandworldwide.com).

About Friedland Capital

Friedland Capital Inc. is a U.S.-based merchant bank and advisory firm with offices or affiliates in New York, Dallas, Denver, Los Angeles, Beijing and Guangzhou. Among its activities, Friedland Capital provides corporate finance advisory services to enable publicly-traded and privately-held emerging growth companies, as well as sponsors of investment programs worldwide to achieve their short-term capital goals, and to realize their long-term business objectives.

About Boston Life Sciences, Inc.

Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE(R) molecular imaging agent is in Phase III clinical trials for the diagnosis of Parkinsonian Syndrome (PS) and a Phase II clinical trial for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The Company's research and pre-clinical CNS programs include Inosine for the treatment of stroke, a DAT blocker for the treatment of Parkinson's disease and a second generation technetium-based molecular imaging agent for PS and ADHD. BLSI's current research collaborations include Harvard Medical School and Children's Hospital of Boston.

ALTROPANE is a registered trademark of Boston Life Sciences, Inc. The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Boston Life Sciences' expectations, beliefs, intentions or strategies regarding the future, including the Company's development efforts regarding the Company's ALTROPANE program and the Company's pre-clinical candidates. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on form 10-Q for the quarter ended September 30, 2005, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Boston Life Sciences from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Boston Life Sciences, Inc. is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Boston Life Sciences, Inc.
http://www.bostonlifesciences.com/

• Additional
• References
• Citations